AstraZeneca PLC (LSE:AZN) said its recently acquired Alexion unit is discontinuing a Phase III clinical trial of its Ultomiris medication in adults with amyotrophic lateral sclerosis (ALS).
The drug maker said the Independent Data Monitoring Committee (IDMC) had recommended that the trial be halted due to lack of efficacy.
ALS is a rare, fatal neurodegenerative disease that affects motor neurons in the brain and spinal cord.